RE:RE:RE:RE:RE:RE:BaxterIt's all about the absolute risk reduction. The higher the ARR, the higher the premium pricing for PMX, and the quicker the market penetration for PMX. These are the most important factors for Baxter.
I could see a 2 billion dollar valuation if the ARR is 25%.
I could see a 1.5 billion dollar valuation if the ARR is 20%.
I could see a 1 billion dollar valuation if the ARR is 15%.
These are my guesstimates for both PMX and EAA together. I think we are both in the same ballpark. It's fine if you want to go into a detailed individual guesstimate of PMX, EAA, and Dialco to try and get your valuation as high as possible but I just don't see the point in that because then you are going to have to factor in things like the cost of carry for a BBB rated company like Baxter and the timeline for reaching full enrollment, fda approval and peak market penetration etc.
Now can we all please just sit back and say a little prayer that we did in fact just sign Ohtani.